Biocon Q4 profit drops 57%, but biosimilars business shines
Published on: May 8, 2026, 11:12 a.m. | Source: The Hindu Business Line
Biocon's Q4 profit drops 57% due to exceptional items, but biosimilars and generics segments show strong growth.
ePrescribe
Upgrade your clinic to smart, simple, and paperless management—start today!
Grow. Protect. Prosper.
Your wealth deserves expert care. Our advisors craft personalized investment plans designed to grow and safeguard your assets.
Schedule Call